An­oth­er im­munome­tab­o­lism deal? Johns Hop­kins spin­out Dra­cen lands $36M in­vest­ment from Deer­field

In the sec­ond fi­nanc­ing round an­nounced in one day for an im­munome­tab­o­lism start­up, Johns Hop­kins spin­out Dra­cen Phar­ma­ceu­ti­cals just wrapped up a $36 mil­lion in­vest­ment deal from Deer­field.

This mon­ey was part of a big­ger $40 mil­lion Se­ries A round, which got re­port­ed be­fore the deal ac­tu­al­ly closed.

The com­pa­ny, found­ed just a year ago, is de­vel­op­ing nov­el glu­t­a­mine an­tag­o­nists that work as in­hibitors of can­cer me­tab­o­lism, chok­ing out tu­mors and their nor­mal meta­bol­ic func­tion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.